» Articles » PMID: 33399540

Economic Burden and Health Care Access for Patients With Inflammatory Bowel Diseases in China: Web-Based Survey Study

Overview
Publisher JMIR Publications
Date 2021 Jan 5
PMID 33399540
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The increasing incidence of inflammatory bowel disease (IBD) has imposed heavy financial burdens for Chinese patients; however, data about their financial status and access to health care are still lacking. This information is important for informing patients with IBD about disease treatment budgets and health care strategies.

Objective: The aim of this study was to evaluate the economic status and medical care access of patients with IBD through the China Crohn's & Colitis Foundation web-based platform in China.

Methods: Our study was performed in 14 IBD centers in mainland China between 2018 and 2019 through WeChat. Participants were asked to complete a 64-item web-based questionnaire. Data were collected by the Wenjuanxing survey program. We mainly focused on income and insurance status, medical costs, and access to health care providers. Respondents were stratified by income and the associations of income with medical costs and emergency visit times were analyzed.

Results: In this study, 3000 patients with IBD, that is, 1922 patients with Crohn disease, 973 patients with ulcerative colitis, and 105 patients with undetermined colitis were included. During the last 12 months, the mean (SD) direct and indirect costs for per patient with IBD were approximately US $11,668.68 ($7944.44) and US $74.90 ($253.60) in China. The average reimbursement ratios for most outpatient and inpatient costs were less than 50%. However, the income of 85.5% (2565/3000) of the patients was less than ¥10,000 (US $1445) per month. Approximately 96.5% (2894/3000) of the patients were covered by health insurance, but only 24.7% (741/3000) of the patients had private commercial insurance, which has higher imbursement ratios. Nearly 98.0% (2954/3000) of the patients worried about their financial situation. Thus, 79.7% (2392/3000) of the patients with IBD tried to save money for health care and even delayed their medical treatments. About half of the respondents (1282/3000, 42.7%) had no primary care provider, and 52.2% (1567/3000) of the patients had to visit the emergency room 1-4 times per year for the treatment of their IBD. Multivariate analysis revealed that lower income (P=.001) and higher transportation (P=.004) and accommodation costs (P=.001) were significantly associated with the increased number of emergency visits of the patients.

Conclusions: Chinese patients with IBD have enormous financial burdens and difficulties in accessing health care, which have increased their financial anxiety and inevitably influenced their disease outcomes. Early purchase of private insurance, thereby increasing the reimbursement ratio for medical expenses, and developing the use of telemedicine would be effective strategies for saving on health care costs.

Citing Articles

Translation, cross-cultural adaptation and validation of the Chinese version of the IBD-Control questionnaire: A patient-reported outcome measure in inflammatory bowel disease.

Guo B, Li H, Cui Q, Li J, Yu Y, Li Z PLoS One. 2024; 19(12):e0311529.

PMID: 39666734 PMC: 11637382. DOI: 10.1371/journal.pone.0311529.


An uncertain future: perspectives of emerging adults with inflammatory bowel disease-a qualitative semistructured interview study in eastern China.

Zhou Y, Qiao R, Ding T, Li H, Zhang P BMJ Open. 2024; 14(11):e089213.

PMID: 39557559 PMC: 11574518. DOI: 10.1136/bmjopen-2024-089213.


Anti-TNFα in inflammatory bowel disease: from originators to biosimilars.

Zeng Z, Lin H, Jiang M, Yuan J, Li X, Jia Y Front Pharmacol. 2024; 15:1424606.

PMID: 39114362 PMC: 11303209. DOI: 10.3389/fphar.2024.1424606.


Safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of olamkicept: Results from randomized, placebo-controlled, first-in-human phase I trials.

Wagner F, Schreiber S, Bagger Y, Bruzelius K, Falahati A, Sternebring O Clin Transl Sci. 2024; 17(5):e13832.

PMID: 38769747 PMC: 11106552. DOI: 10.1111/cts.13832.


Establishing a machine learning model based on dual-energy CT enterography to evaluate Crohn's disease activity.

Li J, Xie G, Tang W, Zhang L, Zhang Y, Zhang L Insights Imaging. 2024; 15(1):115.

PMID: 38735018 PMC: 11089021. DOI: 10.1186/s13244-024-01703-x.


References
1.
You X, Kobayashi Y . The new cooperative medical scheme in China. Health Policy. 2009; 91(1):1-9. DOI: 10.1016/j.healthpol.2008.11.012. View

2.
Lichtenstein G, Shahabi A, Seabury S, Lakdawalla D, Diaz Espinosa O, Green S . Lifetime Economic Burden of Crohn's Disease and Ulcerative Colitis by Age at Diagnosis. Clin Gastroenterol Hepatol. 2019; 18(4):889-897.e10. DOI: 10.1016/j.cgh.2019.07.022. View

3.
Elkjaer M, Shuhaibar M, Burisch J, Bailey Y, Scherfig H, Laugesen B . E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut. 2010; 59(12):1652-61. DOI: 10.1136/gut.2010.220160. View

4.
Rubin D, Feld L, Goeppinger S, Margolese J, Rosh J, Rubin M . The Crohn's and Colitis Foundation of America Survey of Inflammatory Bowel Disease Patient Health Care Access. Inflamm Bowel Dis. 2016; 23(2):224-232. DOI: 10.1097/MIB.0000000000000994. View

5.
Lei X, Lin W . The New Cooperative Medical Scheme in rural China: does more coverage mean more service and better health?. Health Econ. 2009; 18 Suppl 2:S25-46. DOI: 10.1002/hec.1501. View